Amarin Corporation to Host Investor Conference Call on Thursday, May 13, 2010

Wednesday, May 12, 2010 Press Release J E 4

DUBLIN and MYSTIC, Conn., May 12 Amarin Corporation plc (Nasdaq: AMRN) has scheduled a conference call for Thursday, May 13, 2010 at 4:00 p.m. GMT (11:00 a.m. Eastern Time) to discuss selected financial results and provided a progress update of the Company's ANCHOR and MARINE trials, the two pivotal Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.

The conference call may be heard live via the investor relations section of the Company's website at and will also be available by dialing the following numbers:

Replay is available will be made available for a period of two weeks following the conference calls. To hear a replay of the call dial 1-201-612-7415 (outside U.S.) 1-877-660-6853 (inside U.S.). For both dial in numbers please use account number is 286 and conference id 350729.

About Amarin

Amarin is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), has commenced enrolment of patients in two pivotal Phase 3 clinical trials for the treatment of patients with very high triglyceride levels and for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials were designed under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit

From outside U.S. dial-in: (201) 689-8565 From inside U.S. dial-in: (877) 407-0778

SOURCE Amarin Corporation plc


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Aeterna Zentaris to Present at Upcoming Rodman & R...
Amilpar -- Consolidated Revenues Grow 64% and EBIT...